每周股票复盘：天域生物（603717）实控人变更及定增4.65亿

Core Viewpoint - Tianyu Biological (603717) has experienced a decline in stock price and market capitalization, with significant changes in shareholder structure and financial performance reported in recent disclosures [1][2][3]. Group 1: Stock Performance - As of August 29, 2025, Tianyu Biological's stock closed at 8.26 yuan, down 3.73% from the previous week [1]. - The stock reached a peak of 9.25 yuan on August 25, 2025, and a low of 8.09 yuan on August 28, 2025 [1]. - The company's current total market capitalization is 2.397 billion yuan, ranking 23rd in the aquaculture sector and 4866th in the A-share market [1]. Group 2: Shareholder Changes - As of June 30, 2025, the number of shareholders decreased to 20,200, a reduction of 413 shareholders or 2.0% from March 31, 2025 [1]. - The average number of shares held per shareholder increased from 14,100 to 14,400, with an average holding value of 104,100 yuan [1]. - The actual controller of the company has changed to Luo Weiguo following the termination of the concerted action relationship with Shi Dongwei, who relinquished voting rights for 32,338,800 shares [3]. Group 3: Financial Performance - The company's mid-year report for 2025 shows a main revenue of 412 million yuan, a year-on-year decrease of 2.62% [2]. - The net profit attributable to shareholders increased to 10.818 million yuan, a year-on-year rise of 73.68% [2]. - The company reported a negative non-recurring net profit of 19.3017 million yuan, a significant decline of 528.8% year-on-year [2]. Group 4: Corporate Announcements - On August 25, 2025, the company approved a plan to issue A-shares to specific investors, with a maximum of 71,028,297 shares at a price of 6.55 yuan per share, aiming to raise up to 465.2353 million yuan for working capital and debt repayment [3]. - The company has committed to a shareholder return plan for 2025-2027, promising annual cash dividends of at least 10% of distributable profits, and at least 80% when there are no major expenditures [3]. - The company has not faced regulatory penalties in the past five years and has rectified previous issues related to information disclosure and impairment provisions [3].